尿液蛋白质组学揭示脓毒症相关急性肾损伤亚表型的不同免疫特征
该研究前瞻性纳入173例疑似呼吸道感染来源的脓毒症ICU患者(入组时87例无AKI、86例有AKI),AKI患者中66例为AKI-SP1、20例为AKI-SP2(采用三血浆生物标志物分类器)。对入ICU时采集的尿液行适配体蛋白质组学检测5,212种蛋白,比较两亚型尿蛋白丰度、行通路分析、检验与RRT风险和血菌血症的关联,并用LASSO预测AKI-SP2分类。结果:AKI-SP2有117种尿蛋白更高、AKI-SP1有195种更高(FDR<0.05);AKI-SP2富集炎症/中性粒细胞单核细胞趋化(CXCL1、REG3A)和氧化应激(SOD2)相关蛋白,AKI-SP1富集胶原沉积(GP6)、足细胞来源(SPOCK2)、间充质细胞增殖(IL11RA)、抗炎(IL10RB、TREM2)相关蛋白;免疫应答、补体激活和趋化因子信号通路在AKI-SP2上调,细胞黏附通路在AKI-SP1上调。区分两亚型的尿蛋白与区分住院期间RRT风险的蛋白存在重叠;LASSO尿液蛋白质组学模型分类AKI-SP2的平均AUC为0.86(95%CI 0.69-0.99)。结论提示AKI-SP1为修复再生表型、AKI-SP2为免疫炎症表型并与血菌血症相关,尿液蛋白质组学或可无创分类AKI-SP2。
要点
- 脓毒症相关AKI可分为AKI-SP1(66例)和AKI-SP2(20例),两亚型临床结局和治疗反应不同。
- AKI-SP2尿液中炎症/趋化(CXCL1、REG3A)和氧化应激(SOD2)相关蛋白丰度更高,AKI-SP1中胶原沉积(GP6)、足细胞来源(SPOCK2)、间充质增殖(IL11RA)和抗炎(IL10RB、TREM2)相关蛋白更高。
- 免疫应答、补体激活和趋化因子信号通路在AKI-SP2上调,细胞黏附通路在AKI-SP1上调。
- 区分AKI亚型的尿蛋白与区分住院期间RRT风险的蛋白存在重叠,提示共享生物学和潜在治疗靶点。
- LASSO尿液蛋白质组学模型分类AKI-SP2的平均AUC为0.86(95%CI 0.69-0.99),可能用于无创分类。
适用人群与场景
- 前瞻性纳入的173例ICU脓毒症患者,来源为疑似呼吸道感染;入组时87例无AKI、86例有AKI。
- 86例AKI患者中66例分类为AKI-SP1、20例分类为AKI-SP2(采用三血浆生物标志物分类器)。
诊断标准与关键阈值
- AKI亚型分类采用三血浆生物标志物分类器,将AKI患者分为AKI-SP1和AKI-SP2。
研究设计与关键结果
- 研究为前瞻性队列,纳入173例ICU脓毒症患者(87例无AKI、86例有AKI),其中66例为AKI-SP1、20例为AKI-SP2;对入ICU时尿液行适配体蛋白质组学检测5,212种蛋白。
- AKI-SP2有117种尿蛋白丰度更高,AKI-SP1有195种尿蛋白丰度更高(FDR<0.05)。
- AKI-SP2中炎症及中性粒细胞和单核细胞趋化相关蛋白(CXCL1和REG3A)及氧化应激相关蛋白(SOD2)丰度高;AKI-SP1中胶原沉积(GP6)、足细胞来源(SPOCK2)、间充质细胞增殖(IL11RA)、抗炎(IL10RB和TREM2)相关蛋白丰度高。
- 免疫应答、补体激活和趋化因子信号通路在AKI-SP2上调,细胞黏附通路在AKI-SP1上调。
- 区分AKI亚型的尿蛋白与区分住院期间RRT风险的蛋白存在重叠。
- 顶级适配体与基于ELISA的蛋白检测之间相关性不一。
- LASSO衍生的尿液蛋白质组学模型分类AKI-SP2的平均AUC为0.86(95%CI 0.69-0.99)。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为AKI-SP1以修复、再生表型为特征,AKI-SP2以免疫和炎症表型为特征并与血菌血症相关。
- 作者认为识别出的AKI亚型与最终RRT风险之间的共享生物学凸显了潜在治疗靶点。
- 作者认为尿液蛋白质组学可能用于无创分类AKI-SP2。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients with sepsis-induced AKI can be classified into two distinct sub-phenotypes (AKI-SP1, AKI-SP2) that differ in clinical outcomes and response to treatment. The biologic mechanisms underlying these sub-phenotypes remains unknown. Our objective was to understand the underlying biology that differentiates AKI sub-phenotypes and associations with kidney outcomes.
METHODS: We prospectively enrolled 173 ICU patients with sepsis from a suspected respiratory infection (87 without AKI and 86 with AKI on enrollment). Among the AKI patients, 66 were classified as AKI-SP1 and 20 as AKI-SP2 using a three-plasma biomarker classifier. Aptamer-based proteomics assessed 5,212 proteins in urine collected on ICU admission. We compared urinary protein abundances between AKI sub-phenotypes, conducted pathway analyses, tested associations with risk of RRT and blood bacteremia, and predicted AKI-SP2 class membership using LASSO.
MEASUREMENT AND MAIN RESULTS: In total, 117 urine proteins were higher in AKI-SP2, 195 were higher in AKI-SP1 (FDR < 0.05). Urinary proteins involved in inflammation and chemoattractant of neutrophils and monocytes (CXCL1 and REG3A) and oxidative stress (SOD2) were abundant in AKI-SP2, while proteins involved in collagen deposition (GP6), podocyte derived (SPOCK2), proliferation of mesenchymal cells (IL11RA), anti-inflammatory (IL10RB and TREM2) were abundant in AKI-SP1. Pathways related to immune response, complement activation and chemokine signaling were upregulated in AKI-SP2 and pathways of cell adhesion were upregulated in AKI-SP1. Overlap was present between urinary proteins that differentiated AKI sub-phenotypes and proteins that differentiated risk of RRT during hospitalization. Variable correlation was found between top aptamers and ELISA based protein assays. A LASSO derived urinary proteomic model to classify AKI-SP2 had a mean AUC of 0.86 (95% CI: 0.69-0.99).
CONCLUSION: Our findings suggest AKI-SP1 is characterized by a reparative, regenerative phenotype and AKI-SP2 is characterized as an immune and inflammatory phenotype associated with blood bacteremia. We identified shared biology between AKI sub-phenotypes and eventual risk of RRT highlighting potential therapeutic targets. Urine proteomics may be used to non-invasively classify SP2 participants.
参考来源
- Stanaway IB, Morrell ED, Mabrey FL, et al. Urinary proteomics identifies distinct immunological profiles of sepsis associated AKI sub-phenotypes. Crit Care. 2024. PMID: 39695715. doi:10.1186/s13054-024-05202-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。